Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Date

Click to order products ascending

Display 15 Products per page

Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #1

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Market Spotlight: Axial Spondyloarthritis (axSpA)

$1,318.00

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
March 17, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – US, South #2

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – Germany

$599.00

A Germany-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

$599.00

An Italy-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include non-covalent BTK inhibitors, Brukinsa, and CD19-directed CAR-T therapies.
March 17, 2022
Find out more
Disease Analysis: Asthma
Read More
Since its launch as the first fixed-dose combination (FDC) of an inhaled corticosteroid (ICS) and a long-acting beta 2 agonist (LABA), GlaxoSmithKline’s Advair has become a well-established gold-standard therapy in asthma. However, generic competition in Europe, and more recently in the US, marks the end of this successful history.
March 21, 2022
Find out more
Chronic Lymphocytic Leukemia (CLL)
Read More
The CLL treatment paradigm has changed significantly over the past five years, with targeted therapies such as Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors displacing chemotherapy-based treatments for most patients who have CLL.
March 21, 2022
Find out more
Disease Analysis: Chronic Obstructive Pulmonary Disease (COPD)
Read More
The “ABCD” GOLD treatment guidelines focus on exacerbation risk and patient-reported outcomes to determine pharmacological treatment strategies, independent of spirometric value. Dual bronchodilator combinations are being considered as the new gold standard over long-acting muscarinic antagonist Spiriva in the treatment of more severe COPD.
March 21, 2022
Find out more
Disease Analysis: Psoriasis
Read More
First-line treatment of milder forms of psoriasis will continue to be with cheaper, topical medications. Use of more expensive, systemic therapies will continue to be relegated to more severe psoriasis.
March 21, 2022
Find out more
Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)
Read More
Despite Truvada’s and Descovy’s commercial success, PrEP remains underutilized due to poor awareness and lack of/limited reimbursement in some European countries, though uptake is increasing due to recent favorable reimbursement decisions in Germany, Spain, England, Wales, and Northern Ireland, as well as due to Gilead’s marketing efforts. The US has the highest rate of uptake (estimated at 22% of at-risk individuals in 2020) and generates the majority of global PrEP revenues.
March 23, 2022
Find out more
Disease Analysis: Rheumatoid Arthritis
Read More
The rheumatoid arthritis (RA) market is set to experience increasing attrition due to biosimilar competition. The EU market has taken the brunt of biosimilar erosion, with earlier launches and more acceptance of biosimilars compared to other countries. Over time, biosimilar penetration is anticipated to gain more momentum as international real-world evidence builds, with long-term data supporting biosimilar efficacy and safety. This should allow physicians and patients to grow their confidence and familiarity with biosimilars, and encourage uptake.
March 24, 2022
Find out more
Market Spotlight: Myelofibrosis (MF)

$1,318.00

Datamonitor Healthcare estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.
March 24, 2022
Find out more
Market Spotlight: Hypogonadism

$1,318.00

The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
March 24, 2022
Find out more
Disease Analysis: Respiratory Syncytial Virus (RSV) Prevention
Read More
Respiratory syncytial virus (RSV), a member of the Paramyxoviridae family, is an enveloped, non-segmented, single-stranded, negativesense RNA virus. It is a common respiratory virus that is the leading cause of bronchiolitis in infants, and is estimated to be responsible for 22% of all episodes of acute lower respiratory tract infections in young children.
March 25, 2022
Find out more
Market Spotlight: Acute Decompensated Heart Failure (ADHF)

$1,318.00

Approved drugs in the ADHF – preserved ejection fraction (acute HFpEF) space target natriuretic peptide receptors. These drugs are administered via the intravenous route.
March 25, 2022
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *